Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: Results of a 2-year observational algorithm study

Journal of Clinical Psychiatry

Volumn 63, Issue 9, 2002, Pages 782-790

  Adli, Mazda ^a   Berghöfer, Anne ^a   Linden, Michael ^a   Helmchen, Hanfried ^a   Müller Oerlinghausen, Bruno ^a   Mackert, Arthur ^a   Stamm, Thomas ^a   Bauer, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; HALOPERIDOL; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PERAZINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; BECH RAFAELSEN MELANCHOLIA SCALE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; GERMANY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RATING SCALE; REMISSION; SCORING SYSTEM; SIDE EFFECT; SLEEP DEPRIVATION; STANDARDIZATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036738642     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0906     Document Type: Article

References (47)

1. Helmchen H. Current trends of research on antidepressive treatment and prophylaxis. Compr Psychiatry 1979;20:201-214
2. Helmchen H. Gestuftes Vorgehen bei Resistenz gegen Antidepressiva-Therapie. In: Möller HJ, ed. Therapieresistenz unter Antidepressiva-Behandlung. Berlin, Germany: Springer; 1990:237-250
3. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51(6 suppl):39-47
4. Nolen WA, Haffmans J. Treatment of resistant depression: review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Int Clin Psychopharmacol 1989;4: 217-228
5. Möller HJ. Therapieresistenz unter Antidepressiva: Definition, Epidemiologie und Risikofaktoren. In: Bauer M, Berghöfer A, eds. Therapieresistente Depressionen: Aktueller Wissensstand und Leitlinien für die Behandlung in Klinik und Praxis. Berlin, Germany: Springer; 1997:3-15
6. Rush AJ. Preface. In: Rush AJ, ed. Mood Disorders: Systematic Medication Management. Modem Problems of Pharmacopsychiatry, vol 25. Basel, Switzerland: Karger; 1997:vii-viii
7. Summary, Evidence Report/Technology Assessment Number 7: Treatment of depression: newer pharmacotherapies. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1999. AHCPR publication 99-0580
8. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15
9. Thase ME, Rush AJ, Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097
10. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
11. Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psychiatry 1992;49:831-834
12. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
13. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression, Psychiatr Clin North Am 1996;19:371-386
14. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:243-261
15. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-351
16. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998;59 (suppl 20):73-84
17. Linden M, Helmchen H, Mackert A, et al. Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed inpatients. Pharmacopsychiatry 1994;27(suppl):51-53
18. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991;148:695-704
19. Berghöfer A, Müller EB, Bauer M, et al. Sequentielle Behandlungsstrategien zur Vermeidung und Überwindung von Therapieresistenz bei depressiven Erkrankungen. In: Bauer M, Berghöfer A, eds. Therapieresistente Depressionen. Aktueller Wissensstand und Leitlinien für die Behandlung in Klinik und Praxis. Berlin, Germany: Springer; 1997:235-243
20. Bech P, Rafaelsen OJ. The Melancholia Scale: development, consistency, validity and utility. In: Sartorius N, Ban TA, eds. Assessment of Depression. Berlin, Germany: Springer; 1986:259-269
21. World Health Organization. International Classification of Diseases, Ninth Revision. Geneva, Switzerland: World Health Organization; 1978
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
23. Maier WA, Philipp M, Heuser I, et al. Improving depression severity assessment, 1: reliability, internal validity and sensitivity to change of three observer depression scales. J Psychiatry Res 1988;22:3-12
24. Stieglitz RD, Smolka M, Bech P, et al. Bech-Rafaelsen-Melancholie-Skala (BRMS). Handanweisung. G̈ttingen, Sweden: Hogrefe; 1998:18-22
25. Statistical Package for the Social Sciences, Release 9.0. Chicago, Ill: SPSS Inc; 1997
26. O'Reardon JP, Amsterdam JD. Overview of treatment-resistant depression and its management. In: Amsterdam JD, Hornig M, Nierenberg AA, eds. Treatment-Resistant Mood Disorders. Cambridge, Mass: Cambridge University Press; 2001:30-45
27. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
28. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000;14:3-20
29. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, pt 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43
30. Möller HJ, Fischer G, v. Zerssen D. Prediction of therapeutic response in acute treatment with antidepressants: results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci 1987;236:349-357
31. Möller HJ, Krokenberger M, v. Zerssen D. Prediction of short-term outcome of neurotic-depressive inpatients: results of an empirical study of 134 inpatients. Eur Arch Psychiatry Clin Neursci 1993;242:301-309
32. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
33. Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001;2:57-67
34. Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression: a meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999;19:427-434
35. Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:155-158
36. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine vs imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988;145:306-311
37. Bauer M, Adli M, Kiesslinger U, et al. Algorithm-guided treatment vs treatment as usual: randomized trial in inpatients with depression. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
38. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord 1996;36:95-105
39. Hawley CJ, Pattinson HA, Quick SJ, et al. A protocol for the pharmacologic treatment of major depression: a field test of a potential prototype. J Affect Disord 1998;47:87-96
40. Rush AJ, Rago WV, Crismon ML, et al. Medication treatment for the severely and persistently ill: the Texas Medication Algorithm Project. J Clin Psychiatry 1999;60:284-291
41. Trivedi MH, Rush AJ, Crismon ML, et al. The Texas Medication Algorithm Project (TMAP): outcomes for persons with major depressive disorder. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10-14, 2000; San Juan, Puerto Rico
42. Rush AJ. Issues in implementing algorithms: Texas Medication Algorithm Project (TMAP) and STAR*D experiences. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
43. Adli M, Kiesslinger U, Bauer M, et al. Theorie und praktische Beispiele für die Formulierung von Therapiealgorithmen in Psychiatrie und Psychotherapie [abstract]. Nervenarzt 2000;71(suppl):62
44. Goldner EM, Bilsker D. Evidence-based psychiatry. Can J Psychiatry 1995;40:97-101
45. Andrews G. Randomized controlled trials in psychiatry: important but poorly accepted. BMJ 1999;319:562-564
46. Berner MM, Rüther A, Stieglitz RD, et al. Evidence-based medicine in psychiatry [in German]. Nervenarzt 2000;71:173-180
47. Linden M. Therapeutic standards in psychopharmacology and medical decision making. Pharmacopsychiatry 1994;27(suppl):41-45